Off-Label Use
More Information on Off-Label Use
- Letter to Congress Opposing Draft Legislation That Would Expand Promotion of Medical Products for Unapproved Uses, July 11, 2017
- Letter to Congress Opposing Legislation That Would Expand Promotion of Medical Products for Unapproved Uses, June 5, 2017
- Comments to the FDA on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products, April 19, 2017
- Testimony Before the FDA’s Public Hearing on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products, November 9, 2016
- Press Statement: Lawmakers’ Proposal Would Turn Patients Into Guinea Pigs, May 27, 2016
- Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010, December 16, 2010
- Allergan v. FDA (Can the FDA enforce regulations that restrict the promotion of off-label uses?), December 21, 2009
- Comments on Draft Guidance for Industry on Off-Label Promotion of Drugs and Medical Devices, April 21, 2008
- Letter Urging Action Against a Campaign Promoting the Unapproved Use of Topiramate (Topamax) for Treating Alcoholics, October 9, 2007
- Public Citizen v. FDA (Seeking data on drug company payments to doctors), February 26, 2004
- Public Citizen v. FDA, Agouron Pharmaceuticals, et al (Seeking records on off-label uses), June 9, 2000